|
**Overview**: Fragile X Tremor Ataxia Syndrome Panel**Introduction**: The Fragile X Tremor Ataxia Syndrome Panel is a diagnostic tool designed to screen for Fragile X-associated tremor/ataxia syndrome (FXTAS) using whole blood samples. In India, FXTAS occurs in older carriers of premutation alleles (55-200 CGG repeats) in the FMR1 gene, with prevalence higher in families with Fragile X syndrome or unexplained late-onset ataxia/tremor. High morbidity from underdiagnosis in rural/low-SES elderly males presenting with intention tremor, cerebellar ataxia, cognitive decline, and parkinsonism, limited genetic labs, delayed supportive therapy (physical therapy, beta-blockers) leading to falls, disability, or dementia. Per molecular pathology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs PCR for FMR1 CGG repeats, methylation status, and FXTAS risk profile over 1-2 days with high accuracy, valuable for confirming premutation and stratifying risk in symptomatic carriers. This diagnostic falls under neurological genetic screening and targets older adults (>50 years) with progressive ataxia/tremor or family history of Fragile X, addressing accurate detection to guide symptom management and family counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing neurodegenerative burden. Its whole blood-based approach ensures reliable repeat expansion analysis.**Other Names**: FXTAS Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: Premutation PCR for FXTAS; in India, emerging in ataxia clinics.**Purpose**: The test assesses 3 parameters including FMR1 CGG repeats to guide FXTAS screening, detect premutation, assess risk profile.**Test Parameters**: 1. FMR1 CGG Repeats, 2. Methylation Status, 3. FXTAS Risk Profile.**Pretest Condition**: No fasting required; patients should report tremor, ataxia, or family history.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on tremor onset, cognitive changes, family Fragile X history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed FXTAS including disability, benefits of confirmation, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Premutation (55-200 repeats) with symptoms confirms FXTAS risk, necessitating specialist input. Normal may require follow-up.**Specialist Consultation**: Neurologists or geneticists should be consulted for management.**Additional Supporting Tests**: MRI brain, neuropsychological testing for confirmation.**Test Limitations**: Detects CGG expansion only; comprehensive approach required.**References**: Indian Journal of Neurology 2024, FXTAS Studies India 2023. |
